The INVEST trial was a multicenter RCT testing whether vertebroplasty actually works — or whether its benefits are nonspecific. 131 patients with painful osteoporotic vertebral compression fractures were randomized to vertebroplasty or a carefully matched sham procedure (same room, same sedation, same skin infiltration, methacrylate odor simulated — no needle, no cement).
Before INVEST (and its companion Buchbinder trial, published the same NEJM issue), vertebroplasty had been endorsed by guidelines and widely adopted based on unblinded case series showing dramatic pain relief. The assumption was that PMMA stabilization was the active mechanism.
This trial showed that a sham procedure — with no cement. Produced identical outcomes at 1 month. When you see an elderly patient with a new osteoporotic VCF failing conservative management, this paper is why you should counsel them carefully: the procedure may work, but much of the benefit may be nonspecific.
The practical implication: optimize medical management first (analgesics, bracing, osteoporosis treatment), and frame vertebroplasty as an option for refractory pain with realistic expectations. Not a guaranteed fix.
One important nuance: the 51% crossover rate in the sham group suggests real-world patients who know they got placebo vote with their feet. The question of whether vertebroplasty benefits a specific subgroup (very acute fractures, severe pain, particular morphology) remains open and has driven subsequent research into better patient selection.
The INVEST trial was a multicenter RCT testing whether vertebroplasty actually works — or whether its benefits are nonspecific. 131 patients with painful osteoporotic vertebral compression fractures were randomized to vertebroplasty or a carefully matched sham procedure (same room, same sedation, same skin infiltration, methacrylate odor simulated — no needle, no cement).
Before INVEST (and its companion Buchbinder trial, published the same NEJM issue), vertebroplasty had been endorsed by guidelines and widely adopted based on unblinded case series showing dramatic pain relief. The assumption was that PMMA stabilization was the active mechanism.
This trial showed that a sham procedure — with no cement. Produced identical outcomes at 1 month. When you see an elderly patient with a new osteoporotic VCF failing conservative management, this paper is why you should counsel them carefully: the procedure may work, but much of the benefit may be nonspecific.
The practical implication: optimize medical management first (analgesics, bracing, osteoporosis treatment), and frame vertebroplasty as an option for refractory pain with realistic expectations. Not a guaranteed fix.
One important nuance: the 51% crossover rate in the sham group suggests real-world patients who know they got placebo vote with their feet. The question of whether vertebroplasty benefits a specific subgroup (very acute fractures, severe pain, particular morphology) remains open and has driven subsequent research into better patient selection.